Lilly’s prasugrel found effective to clopidogrel in reducing clots

In this trial, Prasugrel has reduced the relative risk of coronary stent thrombosis (a new clot at the implanted stent site) over clopidogrel by 52% (1.13% versus 2.35%, p<0.0001). In patients who received drug-eluting stents (DES), treatment with prasugrel reduced relative risk by 64% over clopidogrel (0.84% versus 2.31%, p<0.0001), and by 48% in patients who received bare metal stents (BMS) (1.27% versus 2.41%, p=0.0009). A 19% reduction in risk was observed with prasugrel compared with clopidogrel among all patients receiving a stent (9.7% versus 11.9%, p=0.0001) in Triton's primary endpoint of cardiovascular death, non-fatal heart attack, or non-fatal stroke. A 20% relative reduction favoring prasugrel was observed in the primary endpoint in patients who received only a bare metal stent (10% versus 12.2%, p=0.003), and in patients who received only a drug-eluting stent, results showed an 18 percent relative reduction in the primary endpoint favoring prasugrel (9% versus 11.1%, p=0.019). Anthony Ware, Lilly's vice president for cardiovascular/acute care, said: "The reduction in risk seen in patients in this analysis treated with prasugrel over patients treated with clopidogrel is encouraging for high-risk patients with acute coronary syndrome being managed with percutaneous coronary intervention."